Search

  • Sort by

  • Category

  • Post Type

  • Reset

House Resolution demands open access to WHOIS Results

March 3, 2020
Posted in ,

WHOIS data is searchable registrar information available for all websites on the Internet. It has long been used to trace criminal websites that host counterfeit and illicit drug sales, human trafficking, child pornography, and illicit and copyrighted content, as well as the websites of spammers, denial-of-services and phishing attackers, and other fraudsters.

Read More

Astorga_et_al_Indictment

March 2, 2020
Posted in
Read More

CSTI Statement WHOIS House Resolution_2.27.2020

March 2, 2020
Read More
photo of Josh Holton

Tennessean’s Life Cut Short After Following Journalist’s Advice

March 2, 2020
Posted in ,

20-year-old Joshua Holton died of fentanyl poisoning in Tennessee after he took Xanax he’d bought online. He’d seen a TED talk online that suggested that users reviews were a reliable way to judge the quality of the drugs they were selling—but they weren’t.

Read More

Tennessean’s Life Cut Short After Following Journalist’s Advice

March 2, 2020
Posted in
Read More

Joshua Holton

March 2, 2020
Posted in
Read More
photo of Ujjal Dosanjh

Canadian drug importation is “an economic fantasy,” former Canadian health minister says.

March 2, 2020
Posted in ,

In this editorial in The Globe and Mail, Ujjal Dosanjh, formerly a federal minister of health and a premier of British Columbia, explains that drug manufacturers have no incentive to sell Canadian provinces more medicine to fill the needs of U.S. residents. Importation will lead to drug shortages in Canada and counterfeit drug trafficking to the U.S.

Read More

354px-Ujjal_Dosanjh2011

March 2, 2020

Ujjal Dosanjh Source: Dave Chan / CC BY (https://creativecommons.org/licenses/by/2.0)

Read More

Web-banners-HHS-opinions-7-1220

February 28, 2020
Read More

A Letter from the FDA rejecting the certification of Oregon’s Pioneer Prescription Drug Program, 2005

February 28, 2020
Posted in

A Letter to Oregon Governor Theodore R. Kulongoski from Randall W. Lutter, Ph.D., FDA’s Acting Associate Commissioner for Policy and Planning, October 14, 2005

Read More